Puma Biotechnology (PBYI) Capital Expenditures Growth (1y) (2012 - 2025)
Powered by 
Analysis
Puma Biotechnology (PBYI) Capital Expenditures Growth (1y) (2012 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -325.00% |
| Sep 30, 2025 | 30.00% |
| Jun 30, 2025 | 0.00% |
| Dec 31, 2024 | -64.44% |
| Sep 30, 2024 | -25.93% |
| Dec 31, 2023 | 100.64% |
| Sep 30, 2023 | -99.61% |
| Dec 31, 2018 | -46.72% |
| Sep 30, 2018 | 131.06% |
| Jun 30, 2018 | 433.33% |
| Mar 31, 2018 | -31.45% |
| Dec 31, 2017 | -146.50% |
| Sep 30, 2017 | 103.08% |
| Jun 30, 2017 | -99.17% |
| Mar 31, 2017 | 181.82% |
| Dec 31, 2016 | 844.07% |
| Sep 30, 2016 | -57.24% |
| Jun 30, 2016 | 917.13% |
| Mar 31, 2016 | -89.89% |
| Dec 31, 2015 | -89.19% |